Ruxolitinib in Seborrheic Dermatitis

NCT05787860 | Completed Phase 2 Results FDA Drug

• 1 other identifier: GCO 22-0672
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

This study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to baseline profiles in healthy control subjects.

Conditions

Seborrheic Dermatitis

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Investigator Global Assessment of 0 or 1 at Week 4

  Number of Participants with Investigator Global Assessment of 0 or 1 at Week 4 IGA Scale from 0-4 Clear 0 No signs of SD Almost Clear 1 Just perceptible erythema and just perceptible scaling Mild 2 Mild erythema and mild scaling Moderate 3 Moderate erythema and moderate scaling Severe 4 Severe erythema and severe scaling

  At end of Treatment, Week 4

Secondary Outcomes (8)

• Change in Investigator Global Assessment From Baseline to Week 4

  Baseline and Week 4

• Mean Change in Seborrheic Dermatitis Severity Score

  Baseline, Week 4, Week 6

• Mean Change in Seborrheic Dermatitis Severity Score for Scale

  Baseline, Week 4, and Week 6

• Change in Seborrheic Dermatitis Severity Score for Erythema

  Baseline, Week 4, and Week 6

• Change in Seborrheic Dermatitis Severity Score for Pruritus

  Baseline Week 4, and Week 6

Study Arms (2)

Ruxolitinib Cream

ACTIVE COMPARATOR

Participants will receive topical ruxolitinib 1.5% cream

Drug: Ruxolitinib 1.5% Cream

Healthy Control Subjects

NO INTERVENTION

Age- and gender-matched healthy control subjects

Interventions

Ruxolitinib 1.5% Cream DRUG

topical ruxolitinib 1.5% cream twice daily for 4 weeks

Ruxolitinib Cream

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects ≥ 18 years of age at the time of signing the informed consent document.
• Subject is able to understand and voluntarily sign an informed consent document prior to participation in any study assessments or procedures.
• Subject is able to adhere to the study visit schedule and other protocol requirements.
• Baseline SD score of IGA ≥ 3 with facial involvement
• Subject agrees to discontinue all treatments for SD from screening through study completion aside from the study drug
• Subject has failed an adequate course of treatment with at least one available therapy (topical antifungals or low-potency topical corticosteroids)
• Subject is judged to be in otherwise good overall health as judged by the investigator, based on medical history, physical examination, and laboratory testing. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).
• Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on the study drug and for at least 90 days after the last application of the study drug, male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
• Option 1: Any one of the following highly effective contraceptive methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy, OR:
• Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural \[animal\] membrane \[for example, polyurethane\]); PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
• The female subject's chosen form of contraception must be effective by the time the female subject is enrolled into the study.
• Male or female subjects ≥ 18 years of age at the time of signing the informed consent document.
• Subject is able to understand and voluntarily sign an informed consent document prior to participation in any study assessments or procedures.
• Subject does not currently have and does not have a history of SD.
• Female of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline

You may not qualify if:

• The presence of any of the following will exclude a subject from enrollment:
• SD clinical severity of IGA \<3 and SD Severity Score \<6.
• Subjects with other skin diseases that would interfere with the study assessment in the opinion of the investigator.
• Active bacterial, fungal, or viral skin infection within 2 weeks from study initiation.
• Subject has clinically significant (as determined by the investigator) renal, hepatic, hematologic, intestinal, endocrine, pulmonary, cardiovascular, neurological, psychiatric, immunologic, or other major uncontrolled diseases (e.g., malignancy, TB, HIV, HBV, HCV, thromboembolic events) that will affect the health of the subject during the study, or interfere with the interpretation of study results.
• Subject has previously received treatment with oral or topical JAK inhibitors
• Current other topical treatments (e.g., topical corticosteroids, topical calcineurin inhibitors) within 1 week of baseline
• Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic or intralesional corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus within 4 weeks of study initiation
• Concurrent use of strong CYP3A4 inhibitors within 7 days or 5 half-lives (whichever is longer). A list of CYP3A4 inhibiting medications can be found in Appendix 3.
• History of adverse systemic or allergic reactions to any component of the study drug.
• Current participation in any other study with an investigational medication
• Subject who is pregnant or breast feeding
• Active bacterial, fungal, or viral skin infection within 2 weeks from Screening/Baseline visit.
• Subject has uncontrolled clinically significant (as determined by the investigator) renal, hepatic, hematologic, intestinal, endocrine, pulmonary, cardiovascular, neurological, psychiatric, immunologic, or other disease.
• Subject has previously received treatment with oral or topical JAK inhibitors

Sponsors & Collaborators

• Icahn School of Medicine at Mount Sinai: lead
• Incyte Corporation: collaborator

Study Sites (1)

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

Location

MeSH Terms

Conditions

Dermatitis, Seborrheic

Interventions

ruxolitinib

Condition Hierarchy (Ancestors)

Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases; Skin Diseases, Eczematous; Skin Diseases, Papulosquamous

Results Point of Contact

• Title: Giselle Singer
• Organization: Icahn School of Medicine at Mount Sinai

giselle.singer@mssm.edu

212-241-3288

Study Officials

• Benjamin Ungar, MD

  Icahn School of Medicine at Mount Sinai

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Masking Details: Open-Label
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Model Details: Open-Label Trial

Study Record Dates

• First Submitted: March 15, 2023
• First Posted: March 28, 2023
• Study Start: November 15, 2022
• Primary Completion: January 26, 2024
• Study Completion: January 26, 2024
• Last Updated: May 6, 2025
• Results First Posted: May 6, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)